Last $1,100 MXN
Change Today +8.79 / 0.81%
Volume 2.1K
As of 4:08 PM 04/15/14 All times are local (Market data is delayed by at least 15 minutes).

novartis ag-adr (NVSN) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/26/14 - $1,116
52 Week Low
04/17/13 - $879.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NOVARTIS AG-ADR (NVSN)

novartis ag-adr (NVSN) Details

Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, including oncology; primary care and established medicines; specialty care, such as ophthalmology, neuroscience, integrated hospital care, and critical care; and cardiovascular and metabolism. The company’s Alcon division provides various eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye; over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers prescription medicines, as well as pharmaceutical and biotechnological active substances. This division provides active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates, primarily antibiotics; protein or biotechnology-based products; cytotoxic products for the hospital market; and biotech manufacturing services to other companies. The company’s Vaccines and Diagnostics division provides preventive human vaccines. Its Consumer Health division offers over-the-counter medicines comprising readily available consumer medicines; and Animal Health, which provides veterinary products for farm and companion animals. The company distributes its OTC products through various channels, such as food, drug, and mass retail outlets, as well as pharmacies; and Animal Health products directly and through wholesalers of veterinary products. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

135,696 Employees
Last Reported Date: 01/29/14
Founded in 1895

novartis ag-adr (NVSN) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: SFr.3.1M
Chief Financial Officer
Total Annual Compensation: SFr.747.1K
President of Institutes for Biomedical Resear...
Total Annual Compensation: $1.9M
Division Head of Novartis Pharmaceuticals and...
Total Annual Compensation: $2.0M
Division Head of Alcon and Member of Executiv...
Total Annual Compensation: $1.9M
Compensation as of Fiscal Year 2013.

novartis ag-adr (NVSN) Key Developments

Novartis Opens Third Clinical Testing Centre in Philippines

Novartis is opening a third clinical testing centre in the Philippines, having signed a memorandum of understanding with the Philippine Heart Centre (PHC) to establish a Center for Excellence for Clinical Trials (CETC), as reported by Business Mirror. Under the deal, Novartis will be able to make use of the PHC as a priority site for clinical trials in the Philippines, and will provide researcher training to the hospital's clinical team. The focus of research activities will be good clinical practice, pharmacovigilance, biotechnology workshops, and capacity building in relation to clinical trial protocols review.

Sandoz Launches Asthma and COPD Inhaler in Norway

Sandoz has launched AirFluSal Forspiro, a new inhaler for patients with asthma and/or chronic obstructive pulmonary disease, or COPD, in Norway. In Norway, Sandoz is launching the 50/250 µg and 50/500 µg dosage forms for the continuous treatment of patients above 12 years of age with persistent asthma or for symptomatic treatment of COPD. The device features an innovative, patient-friendly design, including multiple feedback mechanisms: visual control features which help reassure the patient about dosing; simple lever arm to load the dose; and clear and accurate dose counter.

Novartis Announces Closing of PARADIGM-HF Trial for Chronic Heart Failure

Novartis  announced that  the Data Monitoring  Committee  (DMC) recommended early closure of the PARADIGM- HF study, indicating  patients with chronic  heart failure with  reduced ejection fraction (HF- REF)  who received LCZ696 lived longer  without being hospitalized for heart  failure  than  those  who  received  standard care with ACE-inhibitor enalapril.  Based on the compelling efficacy and primary endpoint having been met, the trial  will now close early. This follows two previous interim analyses that showed the  safety profile of LCZ696 was acceptable. The  results of PARADIGM- HF will be submitted  to a major medical conference for  presentation  and  Novartis  will  now  initiate  discussions with global health  authorities regarding approval for marketing.  LCZ696,  a twice a day pill for heart failure, is a medicine that   acts  in  multiple  ways  on  the  neurohormonal  systems of the heart, blocking   receptors  exerting  harmful  effects  while simultaneously promoting protective  mechanisms.  Known  as  an  ARNI  (Angiotensin  Receptor  Neprilysin  Inhibitor)  LCZ696  is  thought  to  reduce  the  strain  on  the failing heart,  promoting the ability of the heart muscle to recover.  PARADIGM-HF  is a randomized,  double-blind, Phase III  outcome study evaluating   the  efficacy and safety profile  of LCZ696 versus enalapril  (a widely used ACE  inhibitor)  in 8,436  patients with heart failure with reduced ejection fraction  (HF-REF). The primary outcome is a composite of time to first occurrence  of  either cardiovascular death or heart failure hospitalization, and the trial   is also designed to be able to detect a significant difference in cardiovascular  death. The study  was initiated  in December  2009 and currently  is the largest clinical trial in heart failure ever undertaken.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVSN:MM $1,100.14 MXN +8.79

NVSN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Johnson & Johnson $99.20 USD +2.06
Nestle SA SFr.66.55 CHF -0.30
Pfizer Inc $29.89 USD +0.02
Roche Holding AG SFr.254.60 CHF +1.30
Procter & Gamble Co/The $80.84 USD +0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation NVSN Industry Range
Price/Earnings 22.7x
Price/Sales 3.5x
Price/Book 2.7x
Price/Cash Flow 24.8x
TEV/Sales 3.4x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at